Candriam S.C.A. purchased a new position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,191,401 shares of the company's stock, valued at approximately $7,500,000. Candriam S.C.A. owned approximately 1.20% of Autolus Therapeutics at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in AUTL. Dumont & Blake Investment Advisors LLC bought a new position in shares of Autolus Therapeutics in the 4th quarter worth $35,000. Arkadios Wealth Advisors bought a new position in shares of Autolus Therapeutics in the 4th quarter worth $47,000. Capstone Investment Advisors LLC bought a new position in shares of Autolus Therapeutics in the 3rd quarter worth $51,000. Avanza Fonder AB bought a new position in shares of Autolus Therapeutics in the 4th quarter worth $75,000. Finally, Bellevue Group AG raised its position in shares of Autolus Therapeutics by 27.7% in the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company's stock worth $151,000 after acquiring an additional 9,000 shares in the last quarter. 72.83% of the stock is owned by institutional investors.
Shares of AUTL stock traded down $0.06 during mid-day trading on Friday, reaching $2.01. The stock had a trading volume of 443,981 shares, compared to its average volume of 1,237,897. The business's fifty day moving average is $2.14 and its 200-day moving average is $3.06. The firm has a market cap of $534.85 million, a price-to-earnings ratio of -1.66 and a beta of 2.07. Autolus Therapeutics plc has a 1-year low of $1.68 and a 1-year high of $6.63.
AUTL has been the subject of several recent research reports. Needham & Company LLC reissued a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. The Goldman Sachs Group raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and upped their target price for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Redburn Atlantic raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price on the stock in a research report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $10.40.
Get Our Latest Stock Analysis on AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.